ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0780

Kidney and Clinical Outcomes of COVID-19 in the Mexican Population

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Villegas, Luz Yareli, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Hospital General Regional No.46, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
  • Garcia Rivera, Alejandro, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Hospital General Regional No.46, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
  • Katia yuritzi, Ríos Cornejo, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Hospital General Regional No.46, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
  • Aguilar, Arantxa Karina, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Hospital General Regional No.46, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
  • Lopez, Marcos Adrian Elias, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Hospital General Regional No.46, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
  • Rico sánchez, Jesús Alejandro, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Hospital General Regional No.46, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
  • Villavicencio López, Carlos Alberto, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Hospital General Regional No.46, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
  • Ojeda, Ernesto, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Hospital General Regional No.46, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
  • Alvarez, Carolina Romo, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Hospital General Regional No.46, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
  • Vega López de Nava, Jesús Andres, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Hospital General Regional No.46, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
  • Ayala cortés, Rafael Adalid, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Hospital General Regional No.46, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
  • Salazar Soltero, Luis Alberto, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Hospital General Regional No.46, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
  • Sanchez Vazquez, Omar Humberto, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Hospital General Regional No.46, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
  • Topete reyes, Jorge fernando, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Hospital General Regional No.46, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
Background

Coronavirus Disease 2019 (COVID-19) is a new disease of pandemic proportions. Currently, there are no reports about kidney involvement and the association with mortality in Mexico. Our aim was to describe the characteristics in our population, clinical and renal outcomes.

Methods

Prospective, descriptive, single-center study in patients diagnosed with COVID-19 (positive RT-PCR tests), admitted to our hospital from April 2020 to date.

Results

48 patients (60.41% men) with an average age of 54.33 years were included. 23 (47.9%) had a previous diagnosis of HTN and DM, 11 (22.9%) had obesity, 5 (10.4%) had neurological diseases, 4 (6.3%) had heart disease, 3 (6.3%) had malignancies and 1 (2.1%) had liver disease. 9 (18.8%) patients with a history of smoking. At admission, the mean oxygen saturation was 85.76%. The main reason for consultation was dyspnea in 35 patients (72.9%). Regarding symptoms, 81.3% (39) had dyspnea, 87.5% (42) fever, 54.2% (26) headache, 72.9% (35) cough and, to a lesser extent, odynophagia, myalgia and malaise in 33.3% (16), 45.8% (22) and 41.7% (20) respectively. The mean creatinine, urea and bicarbonate was 1.34 mg/dl, 56.69 mg/dl, and 18.49 mmol/l respectively. 25% of the patients required ICU admission and 27.1% mechanical ventilation. During the study period, 19 patients (39.6%) developed AKI, 20.8% classified as KDIGO stage 1 and 18.8% as stage 3. At the end of this study, 56.3% (27) had a complete recovery, 35.4% (16) died and 8.3% (5) are still admitted. Regarding the patients that had an AKI, 6 (31.57%) had a complete recovery, 3 (15.7%) required intermittent HD but eventually died, for a total of 13 death patients (68.4%). There was a statistically significant difference in mortality between patients with AKI vs patients with normal kidney function (p=0.002), with a RR of 3.47.

Conclusion

This study showed a higher prevalence of AKI in the Mexican population compared to reports from other countries, with a significantly higher risk for death. Special attention should be paid to this outcome and as nephrologists, we must take an active role in the care of these patients.